Objective To investigate the effects of proprotein convertase subtilisin/kexin type-9(PCSK9)inhibitors on lipid profiles,liver and renal function,and recurrent cardiovascular events in patients after myocardial infarction.Methods A total of 106 patients with acute myocardial infarction who were treated at the Renmin Hospital of Wuhan University from 2020 to 2023 were retrospectively collected for this study.Patients were divided into a control group(n=53)and an observation group(n=53)according to the treatment plan.Patients in the control group received statin therapy for lipid-lowering treatment,while patients in the observation group received PCSK9 inhibitors in addition to statin therapy.Both groups of patients received continuous medication for one month and underwent follow-up examinations.The lipid levels,liver and renal function,and echocardiographic parameters before and after treatment were compared between the two groups.Results After treatment,the levels of TCh,LDL-C were lower than before treatment in two groups,and the TCh and LDL-C levels in the observation group were lower than those in the control group(t/P=3.656/＜0.001,4.342/＜0.001),and the levels of TG was lower than before treatment in the observation group.However,there was no significant difference between the comparison of HDL-C levels in the 2 groups after treatment(P＞0.05).After treatment,the levels of ALT and AST in 2 groups were lower than before treatment(t/P=3.877/＜0.001,5.082/＜0.001,10.172/＜0.001,13.644/＜0.001),but there was no difference in the ALT levels between 2 groups after treatment(P＞0.05).There was no difference in the renal function index in 2 groups after treatment and in both 2 groups before and after treatment(P＞0.05).After treatment,the lev-el of LVEF was higher in the observation group(t/P=3.542/0.001),and IVSD in the 2 groups were lower than before treat-ment(t/P=3.005/0.004,3.042/0.004).The incidence of cardiovascular adverse events in the observation group was 3.8％,low-er than 20.8％in the control group(x2/P=7.102/0.008).Conclusion PCSK9 inhibitors can significantly reduce lipid levels and the rate of cardiovascular adverse events in patients with Acute Myocardial Infarction(AMI)and improve cardiac func-tion,with no significant impact on liver and renal function.
Acute myocardial infarctionEvolocumab injectionLipid levelsLiver function and renal functionRe-current cardiovascular adverse eventClinical efficacy
万方数据
维普
